特应性皮炎、银屑病和硬斑病儿科患者的乙型肝炎疫苗应答降低
研究旨在评估银屑病、特应性皮炎或硬斑病患者在开始免疫抑制治疗前对乙型肝炎疫苗的抗体应答率。原文未报告具体样本量、应答率数值及统计学比较结果,结论方向为这些儿科患者的乙肝疫苗应答降低。
要点
- 已识别HIV、炎症性肠病和慢性肾脏病患者为乙肝疫苗高无应答率群体。
- 研究评估银屑病、特应性皮炎或硬斑病患者开始免疫抑制治疗前的乙肝疫苗抗体应答率。
- 原文未报告具体应答率数值及组间比较结果。
核心结论
- 特应性皮炎、银屑病和硬斑病儿科患者对乙型肝炎疫苗的抗体应答降低。
研究设计与样本
- 研究设计与样本量原文未报告;研究对象为银屑病、特应性皮炎或硬斑病患者,评估其在开始免疫抑制治疗前对乙型肝炎疫苗的抗体应答率。
主要发现
- 原文未报告具体抗体应答率数值及组间比较结果。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Multiple groups of patients have been recognized for having high rates of non-responders to the Hepatitis B vaccine including those with HIV, inflammatory bowel disease, and chronic kidney disease. These patients are at increased risk for infection due to both the nature of their underlying diseases and the immunosuppressive drugs they are commonly prescribed. Identification of groups with high non-response rates is essential in order to establish vaccination guidelines and prevent serious infections in already susceptible patients. We thus aimed to assess the rate of antibody response to the HBV vaccine in patients with psoriasis, atopic dermatitis, or morphea prior to starting immunosuppressive therapy.
引用
- Patel DP, Treat JR, Castelo-Socio L, et al. Decreased Hepatitis B vaccine response in pediatric patients with atopic dermatitis, psoriasis, and morphea. Vaccine. 2017. PMID: 28736199. doi:10.1016/j.vaccine.2017.07.025
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。